Ovid Therapeutics Earnings Perspective: Return On Capital Employed
Portfolio Pulse from Benzinga Insights
Ovid Therapeutics (NASDAQ:OVID) reported Q1 sales of $66 thousand and a loss of $13.36 million, a 16.09% decrease from last quarter. The company posted a negative Return on Capital Employed (ROCE) of -0.11%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.19, missing analyst predictions of $-0.17.
May 22, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ovid Therapeutics reported Q1 sales of $66 thousand, a loss of $13.36 million, and a negative ROCE of -0.11%. The company missed analyst predictions with Q1 EPS of $-0.19.
Ovid Therapeutics reported a decrease in earnings and a negative ROCE, suggesting inefficient capital allocation. The company also missed analyst predictions for Q1 EPS. These factors are likely to have a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100